<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Original Research Effect of combinations of antiviral drugs on" exact="herpes" post="simplex encephalitis GebhardtBryan M1FocherFederico2EberleRichard3ManikowskiAndrzej4WrightGeorge E4[1], [2], [3], [4], Correspondence:"/>
 <result pre="Research Effect of combinations of antiviral drugs on herpes simplex" exact="encephalitis" post="GebhardtBryan M1FocherFederico2EberleRichard3ManikowskiAndrzej4WrightGeorge E4[1], [2], [3], [4], Correspondence: George E"/>
 <result pre="kinase inhibitor that prevents encephalitic death in mice caused by" exact="herpes" post="simplex virus (HSV) types 1 and 2, although its"/>
 <result pre="encephalitic death in mice caused by herpes simplex virus (HSV)" exact="types 1 and 2," post="although its potency is somewhat less than that of"/>
 <result pre="or cidofovir (CDF) against HSV encephalitis. BALB/c mice were given" exact="ocular" post="infections with HSV-1 or HSV-2, and treated twice daily"/>
 <result pre="cidofovir (CDF) against HSV encephalitis. BALB/c mice were given ocular" exact="infections" post="with HSV-1 or HSV-2, and treated twice daily intraperitoneally"/>
 <result pre="appeared to be synergistic, ie, protected more mice against HSV-1" exact="encephalitis" post="compared with each drug given alone. Delay of treatment"/>
 <result pre="safe combination therapy for the prevention and/or treatment of HSV" exact="infection of the central nervous system" post="can improve the outcome of this infection in humans."/>
 <result pre="for the prevention and/or treatment of HSV infection of the" exact="central nervous system" post="can improve the outcome of this infection in humans."/>
 <result pre="the central nervous system can improve the outcome of this" exact="infection" post="in humans. antivirals herpetic encephalitis Introduction The major mucocutaneous"/>
 <result pre="improve the outcome of this infection in humans. antivirals herpetic" exact="encephalitis" post="Introduction The major mucocutaneous diseases caused by herpes simplex"/>
 <result pre="antivirals herpetic encephalitis Introduction The major mucocutaneous diseases caused by" exact="herpes" post="simplex virus (HSV) in humans are well managed by"/>
 <result pre="in humans are well managed by existing antiviral drugs, but" exact="neonatal" post="herpes and herpes encephalitis are not.1 The drug of"/>
 <result pre="humans are well managed by existing antiviral drugs, but neonatal" exact="herpes" post="and herpes encephalitis are not.1 The drug of choice"/>
 <result pre="well managed by existing antiviral drugs, but neonatal herpes and" exact="herpes" post="encephalitis are not.1 The drug of choice in the"/>
 <result pre="managed by existing antiviral drugs, but neonatal herpes and herpes" exact="encephalitis" post="are not.1 The drug of choice in the latter"/>
 <result pre="mortality still occurs and considerable morbidity remains for survivors. HSV" exact="encephalitis" post="is the most common form of fatal encephalitis in"/>
 <result pre="survivors. HSV encephalitis is the most common form of fatal" exact="encephalitis" post="in the US. Reports of prevalance of HSV encephalitis2,3"/>
 <result pre="in the US. A detailed survey by the Centers of" exact="Disease" post="Control4 for the years 1988–1997 reported an average of"/>
 <result pre="underestimate, because the causes of 59.5% of 18,680 hospitalizations for" exact="encephalitis" post="were not disclosed.) Herpetic encephalitis results in high mortality,"/>
 <result pre="59.5% of 18,680 hospitalizations for encephalitis were not disclosed.) Herpetic" exact="encephalitis" post="results in high mortality, and survivors are often severely"/>
 <result pre="often severely handicapped. Recent published estimates of the incidence of" exact="neonatal" post="herpes range from one per 3,500–5,000 births3 to three"/>
 <result pre="severely handicapped. Recent published estimates of the incidence of neonatal" exact="herpes" post="range from one per 3,500–5,000 births3 to three per"/>
 <result pre="shed in the birth canal. The infected newborn may experience" exact="localized" post="skin and ocular lesions, viremia, and localized central nervous"/>
 <result pre="birth canal. The infected newborn may experience localized skin and" exact="ocular" post="lesions, viremia, and localized central nervous system lesion development,"/>
 <result pre="newborn may experience localized skin and ocular lesions, viremia, and" exact="localized" post="central nervous system lesion development, usually starting within six"/>
 <result pre="may experience localized skin and ocular lesions, viremia, and localized" exact="central nervous system" post="lesion development, usually starting within six days of birth."/>
 <result pre="lesion development, usually starting within six days of birth. If" exact="infection" post="results in disseminated disease, central nervous system (CNS) disease"/>
 <result pre="six days of birth. If infection results in disseminated disease," exact="central nervous system" post="(CNS) disease occurs in up to 50% of the"/>
 <result pre="If infection results in disseminated disease, central nervous system (CNS)" exact="disease" post="occurs in up to 50% of the infants and"/>
 <result pre="the survivors of CNS involvement, the outcome is bleak, with" exact="psychomotor retardation" post="in 50% to 75% of the survivors. Intravenous acyclovir"/>
 <result pre="is the drug of choice for therapy of newborns with" exact="localized" post="or disseminated HSV disease, although vidarabine and phosphonoformate (PFA)"/>
 <result pre="also been used. Although these treatments have reduced mortality from" exact="encephalitis" post="to 15%, only 50% of survivors develop normally.3 Unfortunately"/>
 <result pre="of survivors develop normally.3 Unfortunately the overall mortality for disseminated" exact="neonatal" post="herpes remains very high (40% to 65%) regardless of"/>
 <result pre="survivors develop normally.3 Unfortunately the overall mortality for disseminated neonatal" exact="herpes" post="remains very high (40% to 65%) regardless of present"/>
 <result pre="a superior antiviral drug which enters the CNS and inhibits" exact="infection" post="and related neurological sequellae. Recently we reported that an"/>
 <result pre="neurological sequellae. Recently we reported that an inhibitor/substrate of HSV" exact="types 1 and 2" post="(HSV-1, HSV-2) thymidine kinases, viz. 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine (HBPG) demonstrated potent"/>
 <result pre="potent antiviral activity in experimental models of HSV reactivation and" exact="encephalitis" post="in mice.6 The lack of activity of closely related"/>
 <result pre="and possible synergism between HBPG and antiherpes drugs against HSV" exact="encephalitis" post="in mice, most significantly with ACV. Materials and methods"/>
 <result pre="HSV-1 and G strain of HSV-2 were obtained from the" exact="American" post="Type Culture Collection (Manassas, VA). All viruses were propagated"/>
 <result pre="and titered on Vero cells, and stored frozen until use." exact="Encephalitis" post="models Six-week-old BALB/c female mice were provided food and"/>
 <result pre="cells, and stored frozen until use. Encephalitis models Six-week-old BALB/c" exact="female" post="mice were provided food and water ad libitum and"/>
 <result pre="and were maintained in an AAALAC accredited animal care facility." exact="Ocular" post="infection Mice were anesthetized by intraperitoneal (IP) injection of"/>
 <result pre="were maintained in an AAALAC accredited animal care facility. Ocular" exact="infection" post="Mice were anesthetized by intraperitoneal (IP) injection of ketamine"/>
 <result pre="gauge needle, and 1 × 105 plaque-forming units (PFU) of" exact="infectious" post="virus were dropped on each cornea.8 The animals were"/>
 <result pre="were returned to their cages to recover from anesthesia. Intranasal" exact="infection" post="Mice were anesthetized as above and infected with 2"/>
 <result pre="as above and infected with 2 × 105 PFU of" exact="infectious" post="virus. Using a sterile pipet tip loaded with 10"/>
 <result pre="cages to recover from anesthesia. Drug treatment Immediately following the" exact="infection" post="and recovery from anesthesia, groups of 10 animals were"/>
 <result pre="am and 7 pm). Animals were observed daily for a" exact="total" post="of 30 days, and the day of death of"/>
 <result pre="in combination. After one hour of adsorption at 37°C, the" exact="viral" post="inoculum was removed, and cells were overlaid with 2.5"/>
 <result pre="calculated based on the number of plaques obtained in the" exact="absence of" post="drugs. Antiviral activity is expressed as EC50. Results Various"/>
 <result pre="Antiviral activity is expressed as EC50. Results Various routes of" exact="infection" post="have been used to establish HSV encephalitis in mice,"/>
 <result pre="Various routes of infection have been used to establish HSV" exact="encephalitis" post="in mice, including intranasal,9 intracerebral and IP,10,11 and intracutaneous.12"/>
 <result pre="including intranasal,9 intracerebral and IP,10,11 and intracutaneous.12 We used primarily" exact="ocular" post="infection (see below) for comparison of drug–drug combination efficacy."/>
 <result pre="intranasal,9 intracerebral and IP,10,11 and intracutaneous.12 We used primarily ocular" exact="infection" post="(see below) for comparison of drug–drug combination efficacy. Mean"/>
 <result pre="comparison of drug–drug combination efficacy. Mean days of death after" exact="infection" post="(MDD) in untreated animals were usually 9–10 with HSV-1"/>
 <result pre="HSV-2 infections. For comparison, in one experiment we used intranasal" exact="infection" post="in which the MDDs for HSV-1 and HSV-2 were"/>
 <result pre="and 9.9 days, respectively. Effect of single drugs on HSV" exact="encephalitis" post="The standard treatment regimen of twice daily IP injections"/>
 <result pre="HBPG protected animals from HSV-1 and/or HSV-2 encephalitic death following" exact="infection" post="by the ocular route in a dose dependent manner."/>
 <result pre="from HSV-1 and/or HSV-2 encephalitic death following infection by the" exact="ocular" post="route in a dose dependent manner. The ED50 values"/>
 <result pre="are consistent with reported activity of the drugs on HSV" exact="encephalitis" post="in mice (see DeClercq and Holý).12 HBPG6 was effective"/>
 <result pre="was effective against both HSV-1 and HSV-2 encephalitis, and was" exact="intermediate" post="in potency compared with ACV and PFA. Infections with"/>
 <result pre="and was intermediate in potency compared with ACV and PFA." exact="Infections" post="with HSV-1 or HSV-2 by the intranasal route were"/>
 <result pre="treatment To compare the ability of HBPG to prevent an" exact="infection" post="and to treat an established infection, the efficacy of"/>
 <result pre="typical regimen (IP twice daily for five days) against HSV-2" exact="encephalitis" post="was measured after initiating treatment one, two, and three"/>
 <result pre="full days after infection. Effect of drug combinations on HSV" exact="encephalitis" post="Combinations of HBPG with the standard antiherpes drugs increased"/>
 <result pre="antiherpes drugs increased survival of mice with HSV-1 and HSV-2" exact="encephalitis" post="over the expected results for simple additivity (Table 2)."/>
 <result pre="the combinations, assuming simple additivity of responses, ie, essentially a" exact="limited" post="isobologram approach.13Table 3 summarizes the results for several combinations."/>
 <result pre="Thus the apparent synergism between ACV and HBPG against HSV" exact="encephalitis" post="involves a completely different mechanism than inhibition of thymidine"/>
 <result pre="HBPG was effective in protecting mice from death caused by" exact="infection" post="with HSV-1 and HSV-2. The compound is intermediate in"/>
 <result pre="caused by infection with HSV-1 and HSV-2. The compound is" exact="intermediate" post="in potency between ACV and PFA, the current drugs"/>
 <result pre="PFA, the current drugs used to treat human cases of" exact="herpes" post="encephalitis and neonatal herpes. The basis for activity of"/>
 <result pre="the current drugs used to treat human cases of herpes" exact="encephalitis" post="and neonatal herpes. The basis for activity of HBPG"/>
 <result pre="drugs used to treat human cases of herpes encephalitis and" exact="neonatal" post="herpes. The basis for activity of HBPG was first"/>
 <result pre="DNA synthesis. Because HBPG is an efficient substrate for the" exact="viral" post="TK6 it is also possible that the monophosphate or"/>
 <result pre="monophosphate and triphosphate of HBPG were weak inhibitors of the" exact="viral" post="(HSV-1) DNA polymerase (Focher, unpublished observations) that is the"/>
 <result pre="to be additive or even synergistic with ACV against HSV-1" exact="encephalitis" post="(Tables 2 and 3), suggesting a mechanism of interaction"/>
 <result pre="TK. Several studies have explored antiherpes combinations active against different" exact="viral" post="targets. For example, a ribonucleotide reductase inhibitor potentiated activity"/>
 <result pre="activities are directed against independent targets. The treatment of HSV" exact="infection" post="in the CNS requires that the drug reach this"/>
 <result pre="at an effective concentration and in a timely manner. HSV" exact="infection" post="of an epithelial surface, for example the nasal passages"/>
 <result pre="concentration and in a timely manner. HSV infection of an" exact="epithelial" post="surface, for example the nasal passages or the cornea,"/>
 <result pre="the cornea, results in entry of the virus into the" exact="peripheral" post="nervous system in two days and the CNS in"/>
 <result pre="days and the CNS in three days. Exactly how many" exact="viral" post="particles reach the CNS initially or how many rounds"/>
 <result pre="particles reach the CNS initially or how many rounds of" exact="viral" post="replication are necessary to produce encephalitis is not known."/>
 <result pre="how many rounds of viral replication are necessary to produce" exact="encephalitis" post="is not known. Temporal studies with HBPG showed that"/>
 <result pre="HSV-2 encephalitic death when treatment was begun two days after" exact="infection" post="(Figure 1). In contrast, little efficacy of ACV was"/>
 <result pre="period postinfection.10 Only the phosphonate compound CDF prevented lethality of" exact="herpes" post="encephalitis when treatment was delayed until four days postinfection.12"/>
 <result pre="postinfection.10 Only the phosphonate compound CDF prevented lethality of herpes" exact="encephalitis" post="when treatment was delayed until four days postinfection.12 The"/>
 <result pre="observation that HBPG exerts a protective effect two days after" exact="infection" post="indicates that the drug penetrates the CNS in a"/>
 <result pre="the CNS in a therapeutically effective concentration and may reduce" exact="viral" post="replication both before and after the development of encephalitis."/>
 <result pre="encephalitis. Questions remaining to be answered include: Exactly how many" exact="viral" post="particles reach the CNS? How much replication must occur"/>
 <result pre="in the CNS? Based on the disastrous consequences of CNS" exact="infection" post="by HSV in encephalitis and neonates and our encouraging"/>
 <result pre="on the disastrous consequences of CNS infection by HSV in" exact="encephalitis" post="and neonates and our encouraging results indicating that mice"/>
 <result pre="encouraging results indicating that mice can be protected against CNS" exact="infection" post="by HBPG and a combination of HBPG and ACV,"/>
 <result pre="P30EY002377 and an unrestricted departmental grant from Research to Prevent" exact="Blindness" post="(both to LSU Eye Center), and by FIRB grant"/>
 <result pre="conflicts of interest in this work. References References 1McGrathNAndersonNECroxsonMCPowellKFHerpes simplex" exact="encephalitis" post="treated with acyclovir: diagnosis and long term outcomeJ Neurol"/>
 <result pre="Neurol Neurosurg Psychiatry1997633213269328248 2WhitleyRJViral encephalitisNew Engl J Med19903232422502195341 3WhitleyRLakemanFHerpes simplex" exact="infections" post="of the central nervous system: therapeutic and diagnostic considerationsClin"/>
 <result pre="1988–1997Clin Infect Dis20023517518212087524 5LipsitchMDavisGCoreyLPotential benefits of a serodiagnostic test for" exact="herpes" post="simplex virus type 1 (HSV-1) to prevent neonatal HSV-1"/>
 <result pre="5LipsitchMDavisGCoreyLPotential benefits of a serodiagnostic test for herpes simplex virus" exact="type 1" post="(HSV-1) to prevent neonatal HSV-1 infectionSex Transm Dis20032939940512170129 6ManikowskiAVerriALossaniAet"/>
 <result pre="test for herpes simplex virus type 1 (HSV-1) to prevent" exact="neonatal" post="HSV-1 infectionSex Transm Dis20032939940512170129 6ManikowskiAVerriALossaniAet al.Inhibition of herpes simplex"/>
 <result pre="to prevent neonatal HSV-1 infectionSex Transm Dis20032939940512170129 6ManikowskiAVerriALossaniAet al.Inhibition of" exact="herpes" post="simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds:"/>
 <result pre="properties, and pharmaco-kinetic studies of N2-phenylguanine derivatives as inhibitors of" exact="herpes" post="simplex virus thymidine kinasesJ Med Chem19953849577837239 8GebhardtBMVarnellEDHillJMKaufmanHEAnimal models of"/>
 <result pre="herpes simplex virus thymidine kinasesJ Med Chem19953849577837239 8GebhardtBMVarnellEDHillJMKaufmanHEAnimal models of" exact="ocular herpes simplex" post="virus infection (rabbits, primates, mice)Handbook of Animal Models of"/>
 <result pre="simplex virus thymidine kinasesJ Med Chem19953849577837239 8GebhardtBMVarnellEDHillJMKaufmanHEAnimal models of ocular" exact="herpes" post="simplex virus infection (rabbits, primates, mice)Handbook of Animal Models"/>
 <result pre="thymidine kinasesJ Med Chem19953849577837239 8GebhardtBMVarnellEDHillJMKaufmanHEAnimal models of ocular herpes simplex" exact="virus infection" post="(rabbits, primates, mice)Handbook of Animal Models of InfectionChapter 110New"/>
 <result pre="kinasesJ Med Chem19953849577837239 8GebhardtBMVarnellEDHillJMKaufmanHEAnimal models of ocular herpes simplex virus" exact="infection" post="(rabbits, primates, mice)Handbook of Animal Models of InfectionChapter 110New"/>
 <result pre="InfectionChapter 110New YorkNY Academic Press1999919926 9DeClercqELuczakMIntranasal challenge of mice with" exact="herpes" post="simplex virus: An experimental model for evaluation of the"/>
 <result pre="efficacy of experimental drugsJ Infect Dis1976133A226236180205 10KernERGlasgowLAOverallJCJrRenoJMBoeziJATreatment of experimental herpesvirus" exact="infections" post="with phosphonoformate and some comparisons with phosphonoacetateAmtimicrob Agents Chemother197814817823"/>
 <result pre="11KernERRichardsJTOverallJCJrGlasgowLAAlteration of mortality and pathogenesis of three experimental herpesvirus hominis" exact="infections" post="of mice with adenine arabinoside 5’-monophosphate, adenine arabinoside, and"/>
 <result pre="Agents Chemother1978135360204250 12DeClercqEHolýAEfficacy of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)- cytosine in various models of" exact="herpes" post="simplex virus infection in miceAntimicrob Agents Chemother1991357017062069375 13ElionGBSingerSHitchingsGHAntagonists of"/>
 <result pre="12DeClercqEHolýAEfficacy of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)- cytosine in various models of herpes simplex" exact="virus infection" post="in miceAntimicrob Agents Chemother1991357017062069375 13ElionGBSingerSHitchingsGHAntagonists of nucleic acid derivatives"/>
 <result pre="of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)- cytosine in various models of herpes simplex virus" exact="infection" post="in miceAntimicrob Agents Chemother1991357017062069375 13ElionGBSingerSHitchingsGHAntagonists of nucleic acid derivatives"/>
 <result pre="al.2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of" exact="herpes" post="simplex and varicella-zoster viruses and a potentiator of acyclovirProc"/>
 <result pre="Res20025615316612367721 17ChoCTFengKKCombined effects of acycloguanosine and humoral antibodies in experimental" exact="encephalitis" post="due to Herpesvirus hominisJ Infect Dis19801424517441012 Figure 1 Efficacy"/>
 <result pre="hominisJ Infect Dis19801424517441012 Figure 1 Efficacy of HBPG against HSV-2" exact="encephalitis" post="in mice after various delays in starting dosing post-infection."/>
 <result pre="two days postinfection (Mann–Whitney U test). Abbreviations: HBPG, 2-phenylamino-6-oxo-9-(4-hydroxybutyl)purine; HSV," exact="herpes" post="simplex virus; MDD, mean day of death. Table 1"/>
 <result pre="of death. Table 1 ED50s of single drugs vs HSV" exact="encephalitis" post="in micea Drug ED50, mg/kgb HSV-1 HSV-2 ACV 82"/>
 <result pre="200 300 cidofovir 3.2 2.4 HBPG 150 103 Notes: aOcular" exact="infection" post="with HSV-1 or HSV-2. bTreatment begun immediately after infection"/>
 <result pre="aOcular infection with HSV-1 or HSV-2. bTreatment begun immediately after" exact="infection" post="and continued twice daily (every 12 hours) IP for"/>
 <result pre="days, in corn oil. Abbreviations: ACV, acyclovir; HBPG, 2-phenylamino-6-oxo-9-(4-hydroxybutyl)purine; HSV," exact="herpes" post="simplex virus; IP intraperitoneal; PFA, phosphonoformate. Table 2 Effect"/>
 <result pre="PFA, phosphonoformate. Table 2 Effect of drug combinations on HSV" exact="encephalitis" post="in micea HBPG dose, mg/kg Drug, dose, mg/kg HSV-1"/>
 <result pre="test; eMann–Whitney U test. Abbreviations: ACV, acyclovir; HBPG, 2-phenylamino-6-oxo-9-(4-hydroxybutyl)purine; HSV," exact="herpes" post="simplex virus; IP intraperitoneal; nt, not tested; PFA, phosphonoformate."/>
 <result pre="3 Effect of drug combinationsa on survival rates from HSV" exact="encephalitis" post="Dose HBPG % Survivorsb Calcd Found HSV-1, ACV +"/>
 <result pre="rate from combination treatment (Table 2). Abbreviations: ACV, acyclovir; HSV," exact="herpes" post="simplex virus; HBPG, 2-phenylamino-6-oxo-9-(4-hydroxybutyl)purine; CDF, cidofovir; PFA, phosphonoformate."/>
</results>
